ArticleCancer medicine2026
Survival of Individuals Diagnosed With High-Risk, Regional, and Metastatic Prostate Cancer by Culturally and Linguistically Diverse Status: A Retrospective Cohort Study Set in Victoria, Australia.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to investigate survival outcomes among individuals with high-risk, regional, and metastatic prostate cancer (PCa) by culturally and linguistically diverse (CALD) status in Victoria, Australia.
methodsIndividuals with high-risk, regional, and metastatic PCa (February 2009-February 2024) registered in the Victorian Prostate Cancer Outcomes Registry (PCOR-Vic), with last follow-up on 31 July 2024. CALD status was derived from study participants' country of birth and subgrouped into: mainly non-English-speaking countries (NESC) (CALD backgrounds), mainly English-speaking countries (MESC) outside Australia (MESC-born), and Australia (reference group). The primary outcomes, all-cause mortality (ACM) and PCa-specific mortality (PCSM), were determined through linkage of PCOR-Vic to Victorian Cancer Registry death data. ACM and PCa-specific survival were estimated using Kaplan-Meier curves and the cumulative incidence function. Weibull parametric survival and Fine-Gray competing-risks regression models, adjusted for sociodemographic and clinical variables, assessed the association of CALD status with ACM and PCSM.
resultsOf 10,024 eligible participants, 32% died. The median survival time (death) was 116 months, and median follow-up time (censoring) was 66 months. CALD individuals had lower 5-year overall survival compared to Australian-born individuals (66% vs. 71%). While unadjusted models suggested higher ACM among CALD individuals (adjusted hazard ratio [aHR] = 1.20, 95% confidence interval [CI] = 1.11-1.30), adjusted models showed lower ACM (aHR = 0.89, 95% CI = 0.82-0.97) and PCSM (adjusted subdistribution hazard [asHR] = 0.86, 95% CI = 0.76-0.96) than Australian-born individuals. There were significant (p-value < 0.05) interactions between CALD and age (older CALD individuals had higher hazard of ACM and PCSM) and CALD and PCa risk category (CALD individuals with regional PCa had higher hazard of ACM).
conclusionsWhile CALD individuals had lower overall survival and higher ACM than Australian-born individuals, CALD individuals exhibited lower ACM and PCSM following adjustments. Interactions of age and PCa risk category with CALD influenced mortality. Contributing factors (e.g., late diagnosis) should be addressed to reduce disparities by CALD status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.